详情请进入 湖南阳光电子学校 已关注：人 咨询电话：0731-85579057 微信号：yp941688, yp94168
With the addition of RenalGuard to its product portfolio, PLC required a more comprehensive online presence. The new site provides expanded information on RenalGuard Therapy and RenalGuard System, comprehensive overviews related to CIN, a form of Acute Renal Failure, professional and patient information related to TMR and the benefits of the CO2 Heart Laser 2, investor relations materials, and updates on the company. It features a new graphic approach for the company, more reflective of its market and audiences.
"Our new web site gives us the ability to provide a wider range of information on our products and their related disease states to clinicians, our investors and to the general public," stated Mark R. Tauscher, President and CEO of PLC Systems Inc. "We see this expansion of informational and educational resources as a vital way to maintain updated communications with all of our constituents and ensure that knowledge and awareness of PLC Systems is current and accurate, in an appealing and easy-to-navigate graphical setting."
RenalGuard(TM) is an investigational system and therapy that targets patients with compromised renal function who may be at risk for CIN, when undergoing cardiovascular imaging procedures. RenalGuard Therapy(TM) is based on initial pre-clinical study data that suggests that initiating and maintaining high urine output during imaging procedures allows the body to rapidly eliminate toxins in contrast media, reducing their harmful effects. The RenalGuard System(TM) is a fully-automated, real-time matched fluid replacement device intended for the at-risk segment of the millions of interventional cardiology and radiology patients undergoing these procedures.
About PLC Systems Inc.
PLC Systems Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Headquartered in Franklin, Mass., PLC pioneered the CO2 Heart Laser System, which cardiac surgeons use to perform CO2 transmyocardial revascularization (TMR) to alleviate symptoms of severe angina. CO2 TMR offers a treatment option for angina patients who suffer from severe coronary artery disease. The CO2 Heart Laser is the world''s first TMR angina relief device cleared for commercial distribution by both the U.S. Food and Drug Administration and Japanese Ministry of Health, Labor and Welfare, and to obtain a CE Mark for European distribution.
The company is currently conducting a pilot clinical safety study of its RenalGuard Therapy and RenalGuard System. RenalGuard Therapy is designed to reduce the toxic effects that contrast media can have on the kidneys. This therapy is based on the theory that creating and maintaining a high urine output is beneficial to patients undergoing imaging procedures where contrast agents are used. The real-time measurement and matched fluid replacement design of the RenalGuard System is intended to ensure that a high urine flow is maintained before, during and after these procedures. This should allow the body to rapidly eliminate contrast, reducing its toxic effects. The RenalGuard System with its matched fluid replacement capability is intended to minimize the risk of over- or under-hydration.
Additional company information can be found at
This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "estimates," "expects," "will" and similar expressions are intended to identify forward- looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including we may not receive necessary regulatory approvals to market our RenalGuard product, the clinical trials for that product may not be successful, the RenalGuard product may not be commercially accepted, operational changes, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in our Quarterly Report on Form 10-Q for the three months ended June 30, 2007, and our other reports filed with the Securities and Exchange Commission.
PLC Systems, PLC Medical Systems, PLC, CO2 Heart Laser, RenalGuard, RenalGuard System and RenalGuard Therapy are trademarks of PLC Systems Inc.
Contact: Mary T. Conway Conway Communications 617-244-9682 mtconway@att.net
Source: PLC Systems Inc.
(整理：吉林PLC培训学校)
湖南阳光电子学校教学特色
